US panel backs experimental GE brain imaging drug Print E-mail
By Wire Reports   
Tuesday, 11 August 2009 16:28
An experimental GE Healthcare brain imaging drug can serve as an additional tool for doctors in evaluating patients with signs of possible movement disorders such as Parkinson's disease, a U.S. medical advisory panel said on Tuesday.

A Food and Drug Administration panel of outside experts, in an 11-2 vote, told the agency that the benefits of using the drug with imaging scans outweighed its few risks. One panelist abstained.

GE Healthcare, a unit of General Electric Co (NYSE:GE), is seeking FDA approval of its radioactive injectable drug, called DaTSCAN, for use with single photon emission computed tomography, or SPECT, imaging scans to help detect the loss of certain neurons in the brain.

The FDA, which is not bound by the panel's recommendation, will weigh the vote before later making an approval decision.

(Reporting by Susan Heavey; editing by Carol Bishopric)




"Featured Content" profiles are meant to provide awareness of these companies to investors in the small-cap and growth equity community and should not in any way come across as a recommendation to buy, sell or hold these securities. BiomedReports is not paid or compensated by newswires to disseminate or report news and developments about publicly traded companies, but may from time to time receive compensation for advertising, data, analytics and investor relation services from various entities and firms. Full disclosures should be read in the 'About Us Section'.

Add this page to your favorite Social Bookmarking websites
Digg! Reddit! Del.icio.us! Mixx! Google! Live! Facebook! Technorati! StumbleUpon! MySpace! Yahoo!

blog comments powered by Disqus
 

Newsletter